GLP-1 Agonists Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology
GLP-1 Agonists Market Summary
Introduction
GLP-1 Agonists are a class of medications that mimic the action of glucagon-like peptide-1, a hormone that regulates blood glucose levels and appetite, making them vital for managing Type 2 Diabetes Mellitus (T2DM) and obesity. Available in parenteral (injectable) and oral forms, they enhance insulin secretion, suppress glucagon release, and slow gastric emptying, offering superior glycemic control and weight loss benefits compared to traditional diabetes treatments. The market operates within the pharmaceutical sector, driven by rising global diabetes and obesity prevalence, increasing demand for effective chronic disease management, and advancements in drug delivery. Innovations in long-acting formulations, oral bioavailability, and combination therapies are shaping the industry, aligning with trends toward personalized medicine, patient convenience, and holistic metabolic health solutions. Novo Nordisk and Eli Lilly dominate as global giants, leveraging extensive portfolios and market reach.
Market Size and Growth Forecast
The global GLP-1 Agonists market is estimated to be valued between USD 38 billion and USD 40 billion in 2025. It is projected to grow at a compound annual growth rate (CAGR) of 10% to 12% from 2025 to 2030, reaching an approximate range of USD 62 billion to USD 70 billion by 2030. This robust growth is driven by escalating chronic disease burdens, expanding therapeutic applications, and strong market leadership by key players.
Regional Analysis
North America holds the largest share of the GLP-1 Agonists market, estimated at 40-45%, with a growth rate of 9-11%. The United States dominates, driven by high T2DM prevalence—over 34 million cases—and obesity rates exceeding 40%, alongside robust healthcare spending and adoption of advanced therapies. Canada contributes with similar trends. Market dynamics include widespread use for obesity management, strong reimbursement frameworks, and innovation leadership by Eli Lilly and Novo Nordisk, reflecting a mature, high-demand market.
Europe accounts for 25-30% of the market, growing at 8-10%. The United Kingdom, Germany, and France lead, supported by universal healthcare systems and rising chronic disease rates. Germany’s focus on diabetes care and the UK’s obesity initiatives drive demand. Trends emphasize cost-effective parenteral formulations, growing oral GLP-1 adoption, and regulatory support for chronic disease management, balancing innovation with accessibility.
Asia Pacific represents 20-25%, with the highest growth rate of 12-14%. China and India are key drivers, with China’s T2DM cases exceeding 140 million and India’s obesity rates rising rapidly. Japan focuses on aging populations. Trends include increasing penetration of generics, local production by firms like Huadong Medicine, and government healthcare investments, reflecting rapid market expansion.
The Rest of the World, including Latin America, the Middle East, and Africa, holds 5-10%, growing at 10-12%. Brazil and South Africa lead with growing diabetes prevalence. Trends prioritize affordable therapies, partnerships with global leaders, and uptake in urban centers, supporting regional healthcare development.
Application Analysis
The market is segmented by application into Type 2 Diabetes Mellitus and Obesity.
Type 2 Diabetes Mellitus applications dominate, accounting for 65-70%, with a growth rate of 9-11%. GLP-1 Agonists manage blood glucose effectively, reducing complications. Trends focus on long-acting injectables, combination therapies, and widespread use in North America and Europe, driven by diabetes prevalence.
Obesity applications hold 30-35%, growing at 11-13%. GLP-1 Agonists promote significant weight loss, expanding their use beyond diabetes. Trends include high demand in the U.S., oral formulations for patient convenience, and growing acceptance in Asia Pacific, reflecting obesity’s rising global burden.
Product Types Analysis
The market is segmented by product types into Parenteral and Oral.
Parenteral GLP-1 Agonists hold 80-85%, growing at 9-11%. Injectables offer proven efficacy and long-acting options like semaglutide. Trends focus on patient-friendly delivery devices and sustained dominance by Novo Nordisk and Eli Lilly.
Oral GLP-1 Agonists account for 15-20%, growing at 12-14%. Oral forms like Rybelsus improve accessibility. Trends include rapid adoption in Europe and Asia Pacific, driven by patient preference and market expansion efforts.
Key Market Players
Key companies include:
Novo Nordisk: A global leader with blockbuster drugs like Ozempic.
Eli Lilly: Dominates with Trulicity and emerging obesity therapies.
GSK: Focuses on innovative formulations.
AstraZeneca: Offers GLP-1 solutions for diabetes.
Sanofi: Targets chronic disease management.
Huadong Medicine: Leads in China’s market.
These firms drive competition through innovation and market reach.
Porter’s Five Forces Analysis
Threat of New Entrants: Low to medium. High R&D costs and regulatory hurdles limit entry, though generics pose a future threat.
Threat of Substitutes: Medium. Insulin and other diabetes drugs compete, but GLP-1’s dual benefits sustain demand.
Bargaining Power of Buyers: Medium. Patients and insurers demand efficacy, with giants like Novo Nordisk holding leverage.
Bargaining Power of Suppliers: Low. Raw material suppliers have minimal influence due to diversified sourcing.
Competitive Rivalry: High. Novo Nordisk and Eli Lilly dominate, driving innovation and pricing competition.
Market Opportunities and Challenges
Opportunities
Diabetes Epidemic: Rising T2DM cases globally drive demand.
Obesity Management: Expanding use boosts growth, especially in North America.
Oral Adoption: Patient-friendly options increase accessibility.
Challenges
High Costs: Expensive therapies limit access in emerging markets.
Regulatory Hurdles: Stringent approvals slow market entry.
Competition: Generics and biosimilars challenge market share.
Introduction
GLP-1 Agonists are a class of medications that mimic the action of glucagon-like peptide-1, a hormone that regulates blood glucose levels and appetite, making them vital for managing Type 2 Diabetes Mellitus (T2DM) and obesity. Available in parenteral (injectable) and oral forms, they enhance insulin secretion, suppress glucagon release, and slow gastric emptying, offering superior glycemic control and weight loss benefits compared to traditional diabetes treatments. The market operates within the pharmaceutical sector, driven by rising global diabetes and obesity prevalence, increasing demand for effective chronic disease management, and advancements in drug delivery. Innovations in long-acting formulations, oral bioavailability, and combination therapies are shaping the industry, aligning with trends toward personalized medicine, patient convenience, and holistic metabolic health solutions. Novo Nordisk and Eli Lilly dominate as global giants, leveraging extensive portfolios and market reach.
Market Size and Growth Forecast
The global GLP-1 Agonists market is estimated to be valued between USD 38 billion and USD 40 billion in 2025. It is projected to grow at a compound annual growth rate (CAGR) of 10% to 12% from 2025 to 2030, reaching an approximate range of USD 62 billion to USD 70 billion by 2030. This robust growth is driven by escalating chronic disease burdens, expanding therapeutic applications, and strong market leadership by key players.
Regional Analysis
North America holds the largest share of the GLP-1 Agonists market, estimated at 40-45%, with a growth rate of 9-11%. The United States dominates, driven by high T2DM prevalence—over 34 million cases—and obesity rates exceeding 40%, alongside robust healthcare spending and adoption of advanced therapies. Canada contributes with similar trends. Market dynamics include widespread use for obesity management, strong reimbursement frameworks, and innovation leadership by Eli Lilly and Novo Nordisk, reflecting a mature, high-demand market.
Europe accounts for 25-30% of the market, growing at 8-10%. The United Kingdom, Germany, and France lead, supported by universal healthcare systems and rising chronic disease rates. Germany’s focus on diabetes care and the UK’s obesity initiatives drive demand. Trends emphasize cost-effective parenteral formulations, growing oral GLP-1 adoption, and regulatory support for chronic disease management, balancing innovation with accessibility.
Asia Pacific represents 20-25%, with the highest growth rate of 12-14%. China and India are key drivers, with China’s T2DM cases exceeding 140 million and India’s obesity rates rising rapidly. Japan focuses on aging populations. Trends include increasing penetration of generics, local production by firms like Huadong Medicine, and government healthcare investments, reflecting rapid market expansion.
The Rest of the World, including Latin America, the Middle East, and Africa, holds 5-10%, growing at 10-12%. Brazil and South Africa lead with growing diabetes prevalence. Trends prioritize affordable therapies, partnerships with global leaders, and uptake in urban centers, supporting regional healthcare development.
Application Analysis
The market is segmented by application into Type 2 Diabetes Mellitus and Obesity.
Type 2 Diabetes Mellitus applications dominate, accounting for 65-70%, with a growth rate of 9-11%. GLP-1 Agonists manage blood glucose effectively, reducing complications. Trends focus on long-acting injectables, combination therapies, and widespread use in North America and Europe, driven by diabetes prevalence.
Obesity applications hold 30-35%, growing at 11-13%. GLP-1 Agonists promote significant weight loss, expanding their use beyond diabetes. Trends include high demand in the U.S., oral formulations for patient convenience, and growing acceptance in Asia Pacific, reflecting obesity’s rising global burden.
Product Types Analysis
The market is segmented by product types into Parenteral and Oral.
Parenteral GLP-1 Agonists hold 80-85%, growing at 9-11%. Injectables offer proven efficacy and long-acting options like semaglutide. Trends focus on patient-friendly delivery devices and sustained dominance by Novo Nordisk and Eli Lilly.
Oral GLP-1 Agonists account for 15-20%, growing at 12-14%. Oral forms like Rybelsus improve accessibility. Trends include rapid adoption in Europe and Asia Pacific, driven by patient preference and market expansion efforts.
Key Market Players
Key companies include:
Novo Nordisk: A global leader with blockbuster drugs like Ozempic.
Eli Lilly: Dominates with Trulicity and emerging obesity therapies.
GSK: Focuses on innovative formulations.
AstraZeneca: Offers GLP-1 solutions for diabetes.
Sanofi: Targets chronic disease management.
Huadong Medicine: Leads in China’s market.
These firms drive competition through innovation and market reach.
Porter’s Five Forces Analysis
Threat of New Entrants: Low to medium. High R&D costs and regulatory hurdles limit entry, though generics pose a future threat.
Threat of Substitutes: Medium. Insulin and other diabetes drugs compete, but GLP-1’s dual benefits sustain demand.
Bargaining Power of Buyers: Medium. Patients and insurers demand efficacy, with giants like Novo Nordisk holding leverage.
Bargaining Power of Suppliers: Low. Raw material suppliers have minimal influence due to diversified sourcing.
Competitive Rivalry: High. Novo Nordisk and Eli Lilly dominate, driving innovation and pricing competition.
Market Opportunities and Challenges
Opportunities
Diabetes Epidemic: Rising T2DM cases globally drive demand.
Obesity Management: Expanding use boosts growth, especially in North America.
Oral Adoption: Patient-friendly options increase accessibility.
Challenges
High Costs: Expensive therapies limit access in emerging markets.
Regulatory Hurdles: Stringent approvals slow market entry.
Competition: Generics and biosimilars challenge market share.
CHAPTER 1 EXECUTIVE SUMMARY
CHAPTER 2 ABBREVIATION AND ACRONYMS
CHAPTER 3 PREFACE
3.1 Research Scope
3.2 Research Sources
3.2.1 Data Sources
3.2.2 Assumptions
3.3 Research Method
Chapter Four Market Landscape
4.1 Market Overview
4.2 Classification/Types
4.3 Application/End Users
CHAPTER 5 MARKET TREND ANALYSIS
5.1 Introduction
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 Threats
CHAPTER 6 INDUSTRY CHAIN ANALYSIS
6.1 Upstream/Suppliers Analysis
6.2 Glp-1 Agonists Analysis
6.2.1 Technology Analysis
6.2.2 Cost Analysis
6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users
CHAPTER 7 LATEST MARKET DYNAMICS
7.1 Latest News
7.2 Merger and Acquisition
7.3 Planned/Future Project
7.4 Policy Dynamics
CHAPTER 8 HISTORICAL AND FORECAST GLP-1 AGONISTS MARKET IN NORTH AMERICA (2020-2030)
8.1 Glp-1 Agonists Market Size
8.2 Glp-1 Agonists Market by End Use
8.3 Competition by Players/Suppliers
8.4 Glp-1 Agonists Market Size by Type
8.5 Key Countries Analysis
8.5.1 United States
8.5.2 Canada
8.5.3 Mexico
CHAPTER 9 HISTORICAL AND FORECAST GLP-1 AGONISTS MARKET IN SOUTH AMERICA (2020-2030)
9.1 Glp-1 Agonists Market Size
9.2 Glp-1 Agonists Market by End Use
9.3 Competition by Players/Suppliers
9.4 Glp-1 Agonists Market Size by Type
9.5 Key Countries Analysis
9.5.1 Brazil
9.5.2 Argentina
9.5.3 Chile
9.5.4 Peru
CHAPTER 10 HISTORICAL AND FORECAST GLP-1 AGONISTS MARKET IN ASIA & PACIFIC (2020-2030)
10.1 Glp-1 Agonists Market Size
10.2 Glp-1 Agonists Market by End Use
10.3 Competition by Players/Suppliers
10.4 Glp-1 Agonists Market Size by Type
10.5 Key Countries Analysis
10.5.1 China
10.5.2 India
10.5.3 Japan
10.5.4 South Korea
10.5.5 Southest Asia
10.5.6 Australia
CHAPTER 11 HISTORICAL AND FORECAST GLP-1 AGONISTS MARKET IN EUROPE (2020-2030)
11.1 Glp-1 Agonists Market Size
11.2 Glp-1 Agonists Market by End Use
11.3 Competition by Players/Suppliers
11.4 Glp-1 Agonists Market Size by Type
11.5 Key Countries Analysis
11.5.1 Germany
11.5.2 France
11.5.3 United Kingdom
11.5.4 Italy
11.5.5 Spain
11.5.6 Belgium
11.5.7 Netherlands
11.5.8 Austria
11.5.9 Poland
11.5.10 Russia
CHAPTER 12 HISTORICAL AND FORECAST GLP-1 AGONISTS MARKET IN MEA (2020-2030)
12.1 Glp-1 Agonists Market Size
12.2 Glp-1 Agonists Market by End Use
12.3 Competition by Players/Suppliers
12.4 Glp-1 Agonists Market Size by Type
12.5 Key Countries Analysis
12.5.1 Egypt
12.5.2 Israel
12.5.3 South Africa
12.5.4 Gulf Cooperation Council Countries
12.5.5 Turkey
CHAPTER 13 SUMMARY FOR GLOBAL GLP-1 AGONISTS MARKET (2020-2025)
13.1 Glp-1 Agonists Market Size
13.2 Glp-1 Agonists Market by End Use
13.3 Competition by Players/Suppliers
13.4 Glp-1 Agonists Market Size by Type
CHAPTER 14 GLOBAL GLP-1 AGONISTS MARKET FORECAST (2025-2030)
14.1 Glp-1 Agonists Market Size Forecast
14.2 Glp-1 Agonists Application Forecast
14.3 Competition by Players/Suppliers
14.4 Glp-1 Agonists Type Forecast
CHAPTER 15 ANALYSIS OF GLOBAL KEY VENDORS
15.1 Novo Nordisk
15.1.1 Company Profile
15.1.2 Main Business and GLP-1 Agonists Information
15.1.3 SWOT Analysis of Novo Nordisk
15.1.4 Novo Nordisk GLP-1 Agonists Revenue, Gross Margin and Market Share (2020-2025)
15.2 Eli Lilly
15.2.1 Company Profile
15.2.2 Main Business and GLP-1 Agonists Information
15.2.3 SWOT Analysis of Eli Lilly
15.2.4 Eli Lilly GLP-1 Agonists Revenue, Gross Margin and Market Share (2020-2025)
15.3 GSK
15.3.1 Company Profile
15.3.2 Main Business and GLP-1 Agonists Information
15.3.3 SWOT Analysis of GSK
15.3.4 GSK GLP-1 Agonists Revenue, Gross Margin and Market Share (2020-2025)
15.4 AstraZeneca
15.4.1 Company Profile
15.4.2 Main Business and GLP-1 Agonists Information
15.4.3 SWOT Analysis of AstraZeneca
15.4.4 AstraZeneca GLP-1 Agonists Revenue, Gross Margin and Market Share (2020-2025)
15.5 Sanofi
15.5.1 Company Profile
15.5.2 Main Business and GLP-1 Agonists Information
15.5.3 SWOT Analysis of Sanofi
15.5.4 Sanofi GLP-1 Agonists Revenue, Gross Margin and Market Share (2020-2025)
Please ask for sample pages for full companies list
Tables and Figures
Table Abbreviation and Acronyms
Table Research Scope of Glp-1 Agonists Report
Table Data Sources of Glp-1 Agonists Report
Table Major Assumptions of Glp-1 Agonists Report
Figure Market Size Estimated Method
Figure Major Forecasting Factors
Figure Glp-1 Agonists Picture
Table Glp-1 Agonists Classification
Table Glp-1 Agonists Applications
Table Drivers of Glp-1 Agonists Market
Table Restraints of Glp-1 Agonists Market
Table Opportunities of Glp-1 Agonists Market
Table Threats of Glp-1 Agonists Market
Table Covid-19 Impact For Glp-1 Agonists Market
Table Raw Materials Suppliers
Table Different Production Methods of Glp-1 Agonists
Table Cost Structure Analysis of Glp-1 Agonists
Table Key End Users
Table Latest News of Glp-1 Agonists Market
Table Merger and Acquisition
Table Planned/Future Project of Glp-1 Agonists Market
Table Policy of Glp-1 Agonists Market
Table 2020-2030 North America Glp-1 Agonists Market Size
Figure 2020-2030 North America Glp-1 Agonists Market Size and CAGR
Table 2020-2030 North America Glp-1 Agonists Market Size by Application
Table 2020-2025 North America Glp-1 Agonists Key Players Revenue
Table 2020-2025 North America Glp-1 Agonists Key Players Market Share
Table 2020-2030 North America Glp-1 Agonists Market Size by Type
Table 2020-2030 United States Glp-1 Agonists Market Size
Table 2020-2030 Canada Glp-1 Agonists Market Size
Table 2020-2030 Mexico Glp-1 Agonists Market Size
Table 2020-2030 South America Glp-1 Agonists Market Size
Figure 2020-2030 South America Glp-1 Agonists Market Size and CAGR
Table 2020-2030 South America Glp-1 Agonists Market Size by Application
Table 2020-2025 South America Glp-1 Agonists Key Players Revenue
Table 2020-2025 South America Glp-1 Agonists Key Players Market Share
Table 2020-2030 South America Glp-1 Agonists Market Size by Type
Table 2020-2030 Brazil Glp-1 Agonists Market Size
Table 2020-2030 Argentina Glp-1 Agonists Market Size
Table 2020-2030 Chile Glp-1 Agonists Market Size
Table 2020-2030 Peru Glp-1 Agonists Market Size
Table 2020-2030 Asia & Pacific Glp-1 Agonists Market Size
Figure 2020-2030 Asia & Pacific Glp-1 Agonists Market Size and CAGR
Table 2020-2030 Asia & Pacific Glp-1 Agonists Market Size by Application
Table 2020-2025 Asia & Pacific Glp-1 Agonists Key Players Revenue
Table 2020-2025 Asia & Pacific Glp-1 Agonists Key Players Market Share
Table 2020-2030 Asia & Pacific Glp-1 Agonists Market Size by Type
Table 2020-2030 China Glp-1 Agonists Market Size
Table 2020-2030 India Glp-1 Agonists Market Size
Table 2020-2030 Japan Glp-1 Agonists Market Size
Table 2020-2030 South Korea Glp-1 Agonists Market Size
Table 2020-2030 Southeast Asia Glp-1 Agonists Market Size
Table 2020-2030 Australia Glp-1 Agonists Market Size
Table 2020-2030 Europe Glp-1 Agonists Market Size
Figure 2020-2030 Europe Glp-1 Agonists Market Size and CAGR
Table 2020-2030 Europe Glp-1 Agonists Market Size by Application
Table 2020-2025 Europe Glp-1 Agonists Key Players Revenue
Table 2020-2025 Europe Glp-1 Agonists Key Players Market Share
Table 2020-2030 Europe Glp-1 Agonists Market Size by Type
Table 2020-2030 Germany Glp-1 Agonists Market Size
Table 2020-2030 France Glp-1 Agonists Market Size
Table 2020-2030 United Kingdom Glp-1 Agonists Market Size
Table 2020-2030 Italy Glp-1 Agonists Market Size
Table 2020-2030 Spain Glp-1 Agonists Market Size
Table 2020-2030 Belgium Glp-1 Agonists Market Size
Table 2020-2030 Netherlands Glp-1 Agonists Market Size
Table 2020-2030 Austria Glp-1 Agonists Market Size
Table 2020-2030 Poland Glp-1 Agonists Market Size
Table 2020-2030 Russia Glp-1 Agonists Market Size
Table 2020-2030 MEA Glp-1 Agonists Market Size
Figure 2020-2030 MEA Glp-1 Agonists Market Size and CAGR
Table 2020-2030 MEA Glp-1 Agonists Market Size by Application
Table 2020-2025 MEA Glp-1 Agonists Key Players Revenue
Table 2020-2025 MEA Glp-1 Agonists Key Players Market Share
Table 2020-2030 MEA Glp-1 Agonists Market Size by Type
Table 2020-2030 Egypt Glp-1 Agonists Market Size
Table 2020-2030 Israel Glp-1 Agonists Market Size
Table 2020-2030 South Africa Glp-1 Agonists Market Size
Table 2020-2030 Gulf Cooperation Council Countries Glp-1 Agonists Market Size
Table 2020-2030 Turkey Glp-1 Agonists Market Size
Table 2020-2025 Global Glp-1 Agonists Market Size by Region
Table 2020-2025 Global Glp-1 Agonists Market Size Share by Region
Table 2020-2025 Global Glp-1 Agonists Market Size by Application
Table 2020-2025 Global Glp-1 Agonists Market Share by Application
Table 2020-2025 Global Glp-1 Agonists Key Vendors Revenue
Figure 2020-2025 Global Glp-1 Agonists Market Size and Growth Rate
Table 2020-2025 Global Glp-1 Agonists Key Vendors Market Share
Table 2020-2025 Global Glp-1 Agonists Market Size by Type
Table 2020-2025 Global Glp-1 Agonists Market Share by Type
Table 2025-2030 Global Glp-1 Agonists Market Size by Region
Table 2025-2030 Global Glp-1 Agonists Market Size Share by Region
Table 2025-2030 Global Glp-1 Agonists Market Size by Application
Table 2025-2030 Global Glp-1 Agonists Market Share by Application
Table 2025-2030 Global Glp-1 Agonists Key Vendors Revenue
Figure 2025-2030 Global Glp-1 Agonists Market Size and Growth Rate
Table 2025-2030 Global Glp-1 Agonists Key Vendors Market Share
Table 2025-2030 Global Glp-1 Agonists Market Size by Type
Table 2025-2030 Glp-1 Agonists Global Market Share by Type
CHAPTER 2 ABBREVIATION AND ACRONYMS
CHAPTER 3 PREFACE
3.1 Research Scope
3.2 Research Sources
3.2.1 Data Sources
3.2.2 Assumptions
3.3 Research Method
Chapter Four Market Landscape
4.1 Market Overview
4.2 Classification/Types
4.3 Application/End Users
CHAPTER 5 MARKET TREND ANALYSIS
5.1 Introduction
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 Threats
CHAPTER 6 INDUSTRY CHAIN ANALYSIS
6.1 Upstream/Suppliers Analysis
6.2 Glp-1 Agonists Analysis
6.2.1 Technology Analysis
6.2.2 Cost Analysis
6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users
CHAPTER 7 LATEST MARKET DYNAMICS
7.1 Latest News
7.2 Merger and Acquisition
7.3 Planned/Future Project
7.4 Policy Dynamics
CHAPTER 8 HISTORICAL AND FORECAST GLP-1 AGONISTS MARKET IN NORTH AMERICA (2020-2030)
8.1 Glp-1 Agonists Market Size
8.2 Glp-1 Agonists Market by End Use
8.3 Competition by Players/Suppliers
8.4 Glp-1 Agonists Market Size by Type
8.5 Key Countries Analysis
8.5.1 United States
8.5.2 Canada
8.5.3 Mexico
CHAPTER 9 HISTORICAL AND FORECAST GLP-1 AGONISTS MARKET IN SOUTH AMERICA (2020-2030)
9.1 Glp-1 Agonists Market Size
9.2 Glp-1 Agonists Market by End Use
9.3 Competition by Players/Suppliers
9.4 Glp-1 Agonists Market Size by Type
9.5 Key Countries Analysis
9.5.1 Brazil
9.5.2 Argentina
9.5.3 Chile
9.5.4 Peru
CHAPTER 10 HISTORICAL AND FORECAST GLP-1 AGONISTS MARKET IN ASIA & PACIFIC (2020-2030)
10.1 Glp-1 Agonists Market Size
10.2 Glp-1 Agonists Market by End Use
10.3 Competition by Players/Suppliers
10.4 Glp-1 Agonists Market Size by Type
10.5 Key Countries Analysis
10.5.1 China
10.5.2 India
10.5.3 Japan
10.5.4 South Korea
10.5.5 Southest Asia
10.5.6 Australia
CHAPTER 11 HISTORICAL AND FORECAST GLP-1 AGONISTS MARKET IN EUROPE (2020-2030)
11.1 Glp-1 Agonists Market Size
11.2 Glp-1 Agonists Market by End Use
11.3 Competition by Players/Suppliers
11.4 Glp-1 Agonists Market Size by Type
11.5 Key Countries Analysis
11.5.1 Germany
11.5.2 France
11.5.3 United Kingdom
11.5.4 Italy
11.5.5 Spain
11.5.6 Belgium
11.5.7 Netherlands
11.5.8 Austria
11.5.9 Poland
11.5.10 Russia
CHAPTER 12 HISTORICAL AND FORECAST GLP-1 AGONISTS MARKET IN MEA (2020-2030)
12.1 Glp-1 Agonists Market Size
12.2 Glp-1 Agonists Market by End Use
12.3 Competition by Players/Suppliers
12.4 Glp-1 Agonists Market Size by Type
12.5 Key Countries Analysis
12.5.1 Egypt
12.5.2 Israel
12.5.3 South Africa
12.5.4 Gulf Cooperation Council Countries
12.5.5 Turkey
CHAPTER 13 SUMMARY FOR GLOBAL GLP-1 AGONISTS MARKET (2020-2025)
13.1 Glp-1 Agonists Market Size
13.2 Glp-1 Agonists Market by End Use
13.3 Competition by Players/Suppliers
13.4 Glp-1 Agonists Market Size by Type
CHAPTER 14 GLOBAL GLP-1 AGONISTS MARKET FORECAST (2025-2030)
14.1 Glp-1 Agonists Market Size Forecast
14.2 Glp-1 Agonists Application Forecast
14.3 Competition by Players/Suppliers
14.4 Glp-1 Agonists Type Forecast
CHAPTER 15 ANALYSIS OF GLOBAL KEY VENDORS
15.1 Novo Nordisk
15.1.1 Company Profile
15.1.2 Main Business and GLP-1 Agonists Information
15.1.3 SWOT Analysis of Novo Nordisk
15.1.4 Novo Nordisk GLP-1 Agonists Revenue, Gross Margin and Market Share (2020-2025)
15.2 Eli Lilly
15.2.1 Company Profile
15.2.2 Main Business and GLP-1 Agonists Information
15.2.3 SWOT Analysis of Eli Lilly
15.2.4 Eli Lilly GLP-1 Agonists Revenue, Gross Margin and Market Share (2020-2025)
15.3 GSK
15.3.1 Company Profile
15.3.2 Main Business and GLP-1 Agonists Information
15.3.3 SWOT Analysis of GSK
15.3.4 GSK GLP-1 Agonists Revenue, Gross Margin and Market Share (2020-2025)
15.4 AstraZeneca
15.4.1 Company Profile
15.4.2 Main Business and GLP-1 Agonists Information
15.4.3 SWOT Analysis of AstraZeneca
15.4.4 AstraZeneca GLP-1 Agonists Revenue, Gross Margin and Market Share (2020-2025)
15.5 Sanofi
15.5.1 Company Profile
15.5.2 Main Business and GLP-1 Agonists Information
15.5.3 SWOT Analysis of Sanofi
15.5.4 Sanofi GLP-1 Agonists Revenue, Gross Margin and Market Share (2020-2025)
Please ask for sample pages for full companies list
Tables and Figures
Table Abbreviation and Acronyms
Table Research Scope of Glp-1 Agonists Report
Table Data Sources of Glp-1 Agonists Report
Table Major Assumptions of Glp-1 Agonists Report
Figure Market Size Estimated Method
Figure Major Forecasting Factors
Figure Glp-1 Agonists Picture
Table Glp-1 Agonists Classification
Table Glp-1 Agonists Applications
Table Drivers of Glp-1 Agonists Market
Table Restraints of Glp-1 Agonists Market
Table Opportunities of Glp-1 Agonists Market
Table Threats of Glp-1 Agonists Market
Table Covid-19 Impact For Glp-1 Agonists Market
Table Raw Materials Suppliers
Table Different Production Methods of Glp-1 Agonists
Table Cost Structure Analysis of Glp-1 Agonists
Table Key End Users
Table Latest News of Glp-1 Agonists Market
Table Merger and Acquisition
Table Planned/Future Project of Glp-1 Agonists Market
Table Policy of Glp-1 Agonists Market
Table 2020-2030 North America Glp-1 Agonists Market Size
Figure 2020-2030 North America Glp-1 Agonists Market Size and CAGR
Table 2020-2030 North America Glp-1 Agonists Market Size by Application
Table 2020-2025 North America Glp-1 Agonists Key Players Revenue
Table 2020-2025 North America Glp-1 Agonists Key Players Market Share
Table 2020-2030 North America Glp-1 Agonists Market Size by Type
Table 2020-2030 United States Glp-1 Agonists Market Size
Table 2020-2030 Canada Glp-1 Agonists Market Size
Table 2020-2030 Mexico Glp-1 Agonists Market Size
Table 2020-2030 South America Glp-1 Agonists Market Size
Figure 2020-2030 South America Glp-1 Agonists Market Size and CAGR
Table 2020-2030 South America Glp-1 Agonists Market Size by Application
Table 2020-2025 South America Glp-1 Agonists Key Players Revenue
Table 2020-2025 South America Glp-1 Agonists Key Players Market Share
Table 2020-2030 South America Glp-1 Agonists Market Size by Type
Table 2020-2030 Brazil Glp-1 Agonists Market Size
Table 2020-2030 Argentina Glp-1 Agonists Market Size
Table 2020-2030 Chile Glp-1 Agonists Market Size
Table 2020-2030 Peru Glp-1 Agonists Market Size
Table 2020-2030 Asia & Pacific Glp-1 Agonists Market Size
Figure 2020-2030 Asia & Pacific Glp-1 Agonists Market Size and CAGR
Table 2020-2030 Asia & Pacific Glp-1 Agonists Market Size by Application
Table 2020-2025 Asia & Pacific Glp-1 Agonists Key Players Revenue
Table 2020-2025 Asia & Pacific Glp-1 Agonists Key Players Market Share
Table 2020-2030 Asia & Pacific Glp-1 Agonists Market Size by Type
Table 2020-2030 China Glp-1 Agonists Market Size
Table 2020-2030 India Glp-1 Agonists Market Size
Table 2020-2030 Japan Glp-1 Agonists Market Size
Table 2020-2030 South Korea Glp-1 Agonists Market Size
Table 2020-2030 Southeast Asia Glp-1 Agonists Market Size
Table 2020-2030 Australia Glp-1 Agonists Market Size
Table 2020-2030 Europe Glp-1 Agonists Market Size
Figure 2020-2030 Europe Glp-1 Agonists Market Size and CAGR
Table 2020-2030 Europe Glp-1 Agonists Market Size by Application
Table 2020-2025 Europe Glp-1 Agonists Key Players Revenue
Table 2020-2025 Europe Glp-1 Agonists Key Players Market Share
Table 2020-2030 Europe Glp-1 Agonists Market Size by Type
Table 2020-2030 Germany Glp-1 Agonists Market Size
Table 2020-2030 France Glp-1 Agonists Market Size
Table 2020-2030 United Kingdom Glp-1 Agonists Market Size
Table 2020-2030 Italy Glp-1 Agonists Market Size
Table 2020-2030 Spain Glp-1 Agonists Market Size
Table 2020-2030 Belgium Glp-1 Agonists Market Size
Table 2020-2030 Netherlands Glp-1 Agonists Market Size
Table 2020-2030 Austria Glp-1 Agonists Market Size
Table 2020-2030 Poland Glp-1 Agonists Market Size
Table 2020-2030 Russia Glp-1 Agonists Market Size
Table 2020-2030 MEA Glp-1 Agonists Market Size
Figure 2020-2030 MEA Glp-1 Agonists Market Size and CAGR
Table 2020-2030 MEA Glp-1 Agonists Market Size by Application
Table 2020-2025 MEA Glp-1 Agonists Key Players Revenue
Table 2020-2025 MEA Glp-1 Agonists Key Players Market Share
Table 2020-2030 MEA Glp-1 Agonists Market Size by Type
Table 2020-2030 Egypt Glp-1 Agonists Market Size
Table 2020-2030 Israel Glp-1 Agonists Market Size
Table 2020-2030 South Africa Glp-1 Agonists Market Size
Table 2020-2030 Gulf Cooperation Council Countries Glp-1 Agonists Market Size
Table 2020-2030 Turkey Glp-1 Agonists Market Size
Table 2020-2025 Global Glp-1 Agonists Market Size by Region
Table 2020-2025 Global Glp-1 Agonists Market Size Share by Region
Table 2020-2025 Global Glp-1 Agonists Market Size by Application
Table 2020-2025 Global Glp-1 Agonists Market Share by Application
Table 2020-2025 Global Glp-1 Agonists Key Vendors Revenue
Figure 2020-2025 Global Glp-1 Agonists Market Size and Growth Rate
Table 2020-2025 Global Glp-1 Agonists Key Vendors Market Share
Table 2020-2025 Global Glp-1 Agonists Market Size by Type
Table 2020-2025 Global Glp-1 Agonists Market Share by Type
Table 2025-2030 Global Glp-1 Agonists Market Size by Region
Table 2025-2030 Global Glp-1 Agonists Market Size Share by Region
Table 2025-2030 Global Glp-1 Agonists Market Size by Application
Table 2025-2030 Global Glp-1 Agonists Market Share by Application
Table 2025-2030 Global Glp-1 Agonists Key Vendors Revenue
Figure 2025-2030 Global Glp-1 Agonists Market Size and Growth Rate
Table 2025-2030 Global Glp-1 Agonists Key Vendors Market Share
Table 2025-2030 Global Glp-1 Agonists Market Size by Type
Table 2025-2030 Glp-1 Agonists Global Market Share by Type
